The Indus division pilots the foray into the Indian domestic speciality generic formulation market, and the focus is on one of the most important therapeutic segment, viz., Gastro, Respiratory, Infection and Pain.

Indus with its 300 strong and well informed field force meets more than one lakh doctors across the country regularly every month. Aurobindo is possibly the first company in the country to have an exclusive specialised field force to meet and sell solutions to the super specialist surgeons in alleviating the problems related to health care. Indus with its 17 different molecules present in its portfolio is expanding its tentacles   and exercising its GRIP over the domestic market.

Indus Aurobindo with its expertise in Cephalosporins R&D, had introduced many cephalosporins into domestic market namely, Cefadroxil, Cefuroxime axetil, Cefpodoxime proxetil, Ceftriaxone, Cefoperazone + Sulbactam and Cefpirome.

Hot on the heels of latest introduction, Cefactam (combination of Cefoperazone + sulbactam) is emerging as a major tool to the surgeons and physicians to tackle the menance of beta-lactamse problem spreading as a major threat to the lives of patients who are in ICU or those undergoing cardiovasuclar, neuro or gastro surgeries.

The most recent breakthrough for Indus is the introduction of Cefpirome the first in the line of the latest 4^th generation cephalosporins.